(Q37624680)

21 August 2017

1 reference

title

Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment (English)

1 reference

21 August 2017

0 references

0 references

Adam M Huber

1

1 reference

21 August 2017

publication date

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

361-374

1 reference

Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11310550-000000000-00000

Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11310550-000000000-00000

Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11310550-000000000-00000

Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11310550-000000000-00000

Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group

21 January 2018

1 reference

12 December 2020

The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

1 reference

12 December 2020

HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis

1 reference

12 December 2020

History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

1 reference

12 December 2020

Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis

1 reference

12 December 2020

Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies

1 reference

12 December 2020

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

1 reference

12 December 2020

MHC Class I overexpression on muscles in early juvenile dermatomyositis

1 reference

12 December 2020

Clinical significance of specific autoantibodies in juvenile dermatomyositis

1 reference

12 December 2020

Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis

1 reference

12 December 2020

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

1 reference

12 December 2020

Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration

1 reference

12 December 2020

Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis

1 reference

12 December 2020

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

1 reference

12 December 2020

Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis

1 reference

12 December 2020

Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis

1 reference

12 December 2020

Juvenile dermatomyositis. Pathophysiology and disease expression

1 reference

12 December 2020

Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study

1 reference

12 December 2020

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

1 reference

12 December 2020

Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyos

1 reference

12 December 2020

Microchimerism in children with rheumatic disorders: what does it mean?

1 reference

12 December 2020

Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK.

1 reference

12 December 2020

Advances in the treatment of juvenile dermatomyositis

1 reference

12 December 2020

Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies.

1 reference

12 December 2020

Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies

1 reference

12 December 2020

Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

1 reference

12 December 2020

Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.

1 reference

12 December 2020

Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.

1 reference

12 December 2020

Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression

1 reference

12 December 2020

Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis

1 reference

12 December 2020

A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children

1 reference

12 December 2020

Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group

1 reference

12 December 2020

Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group

1 reference

12 December 2020

Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance

1 reference

12 December 2020

A novel autoantibody to a 155-kd protein is associated with dermatomyositis

1 reference

12 December 2020

The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospect

1 reference

12 December 2020

Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.

1 reference

12 December 2020

International consensus on preliminary definitions of improvement in adult and juvenile myositis.

1 reference

12 December 2020

New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis

1 reference

12 December 2020

HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap.

1 reference

12 December 2020

Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions.

1 reference

12 December 2020

Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis

1 reference

12 December 2020

Development and validation of the Dermatomyositis Skin Severity Index

1 reference

12 December 2020

Inflammatory myopathies in childhood: correlation between nailfold capillaroscopy findings and clinical and laboratory data.

1 reference

12 December 2020

Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis

1 reference

12 December 2020

Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells

1 reference

12 December 2020

Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.

1 reference

12 December 2020

Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis

1 reference

12 December 2020

Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM).

1 reference

12 December 2020

Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis

1 reference

12 December 2020

Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients

1 reference

12 December 2020

Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire.

1 reference

12 December 2020

Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures

1 reference

12 December 2020

Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies

1 reference

12 December 2020

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases

1 reference

12 December 2020

International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.

1 reference

12 December 2020

Measurement of health status in children with juvenile rheumatoid arthritis

1 reference

12 December 2020

Myositis specific autoantibodies

1 reference

12 December 2020

TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications

1 reference

12 December 2020

Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis

1 reference

12 December 2020

Endothelial cell activation and neovascularization are prominent in dermatomyositis

1 reference

12 December 2020

Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome

1 reference

12 December 2020

The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids

1 reference

12 December 2020

Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

1 reference

12 December 2020

Parvovirus B19 and Onset of Juvenile Dermatomyositis

1 reference

12 December 2020

An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM).

1 reference

12 December 2020

Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis

1 reference

12 December 2020

Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores

1 reference

12 December 2020

Pathogenesis of myositis in children

1 reference

12 December 2020

[Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases]

1 reference

12 December 2020

Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy.

1 reference

12 December 2020

Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.

1 reference

12 December 2020

Chimerism in children with juvenile dermatomyositis

1 reference

12 December 2020

Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence

1 reference

12 December 2020

MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety

1 reference

12 December 2020

US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry

1 reference

12 December 2020

HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies

1 reference

12 December 2020

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

1 reference

12 December 2020

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

1 reference

12 December 2020

Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis

1 reference

12 December 2020

Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis

1 reference

12 December 2020

Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy

1 reference

12 December 2020

10.2165/11310550-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1017657978

0 references

1 reference